Skip to content
Screener

Net Income at other companies

Eli Lilly logo
Eli LillyLLY
$7.1B+25.3%
Amgen logo
AmgenAMGN
$2.38B+65.9%
Viking Therapeutics logo
Viking TherapeuticsVKTX
-$158.33M-247%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
-$43.42M-4.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$166.56M+1.8%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$89.54M-106%

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$3.19B+719%
Enterprise value$3.15B+798%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Reported directly by MBX Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProfitLoss.

The source filing: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026. Open the filing →

Filed
May 7, 2026, 9:03 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-210593

FAQ

What is MBX Biosciences, Inc.'s net income?
MBX Biosciences, Inc. (MBX) reported net income of -$23.52M in Q1 2026.
How has MBX Biosciences, Inc.'s net income changed year-over-year?
MBX Biosciences, Inc.'s net income increased by 1.5% year-over-year, from -$23.88M to -$23.52M.
What is the long-term trend for MBX Biosciences, Inc.'s net income?
Over 2 years (2023 to 2025), MBX Biosciences, Inc.'s net income has grown at a 63.4% compound annual growth rate (CAGR), from -$32.56M to -$86.97M.
What does net income mean?
Net income as the starting point for the indirect method operating cash flow reconciliation.

Ask your AI about MBX Biosciences, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude